PTAB Declines Request to Review Method of Treating Lymphoma Claim

Oct 12, 2017

Reading Time : 1 min

In rejecting petitioner’s anticipation and obviousness challenges, the panel found that several asserted references were not publicly accessible and, therefore, did not qualify as “printed publications.” First, although a clinical study consent form was distributed to approximately 40 prospective patients, there was no evidence that it was distributed to ordinarily skilled artisans, rather than patients. There was also no evidence to show that an interested party would have known to visit a particular oncology website to look for the consent form. Second, although petitioner’s expert testified that a clinical study protocol was “freely disseminated to any referring doctor or patient,” the panel found this testimony insufficient to establish public accessibility because the expert “[did] not identify any particular instances or the timeframe of its dissemination.” Finally, the panel held that petitioner failed to show that the rituximab label was publicly accessible. In rejecting petitioner’s assertion that the rituximab label was made publicly accessible “when Rituxan was approved,” the panel explained that petitioner failed to provide any documentary or testimonial evidence showing that the label was included in the packaging of a disseminated drug product.

The panel also rejected petitioner’s obviousness challenge because it found that the asserted references failed to disclose the particular treatment regimen and dosing amount limitations recited in the challenged claim. In reaching its decision, the panel rejected the assertion that a skilled artisan would have sought to treat low grade non-Hodgkin’s lymphoma patients with the same dosing regimen employed in a study of a wholly different patient population – namely, elderly patients having aggressive non-Hodgkin’s lymphoma. Nor did petitioner sufficiently explain why an ordinarily skilled artisan would have usedarituximab dose of 375 mg/m2, given the reference’s teachings that “doses up to 500 mg/m2” had been used and that “the best dose and schedule of rituximab remain to be established.”

Celltrion, Inc. v. Biogen, Inc., IPR2017-01093 (PTAB October 6, 2017)
[Franklin, Snedden, Harlow (opinion)]

Share This Insight

Previous Entries

IP Newsflash

July 1, 2025

In an appeal from an inter partes review, the Federal Circuit recently clarified that the enablement inquiry applied to prior art references in the context of an anticipation defense differs from the enablement inquiry applied when evaluating the claims of a patent.

...

Read More

IP Newsflash

June 26, 2025

The Northern District of Ohio denied a motion to compel the plaintiff to produce test results referenced in its initial disclosures and complaint. The court found that because the “test results are not facts but rather are opinions,” the information was protected as work product. Furthermore, because that testing would not be used as evidence in the litigation, the defendant was not prejudiced.

...

Read More

IP Newsflash

June 6, 2025

In a precedential opinion, the Federal Circuit definitively held that the Patent Trial and Appeal Board has jurisdiction over IPRs that concern expired patents.

...

Read More

IP Newsflash

June 6, 2025

In a patent infringement litigation in the U.S. District Court for the Eastern District of Texas, Judge Rodney Gilstrap denied a joint motion to stay the litigation pending resolution of inter partes review when it was uncertain that all defendants would be bound by the statutory estoppel provision of 35 U.S.C. § 315(e).

...

Read More

IP Newsflash

May 30, 2025

A district court recently dismissed a patent infringement complaint for improper venue under 28 U.S.C. § 1400(b), finding that the storage and distribution of products from an Amazon warehouse was not sufficient to establish that warehouse as a regular and established place of business in the district.

...

Read More

IP Newsflash

May 27, 2025

The Federal Circuit affirmed a District of Delaware finding of non-infringement in an ANDA litigation due to the patentee’s clear and unmistakable disavowal of claim scope during prosecution. Specifically, the court held that statements made during prosecution of a parent application before the asserted claims were allowed amounted to a prosecution disclaimer that extended to subsequent patents in the family. In reaching this conclusion, the court rejected an attempt by the patentee to resurrect the claim scope through a unilateral, self-serving statement made in later applications in the family.

...

Read More

IP Newsflash

May 13, 2025

The Federal Circuit recently affirmed a district court’s holding that patent term extension (PTE) for a reissued patent was properly based on the issue date of the original patent and not that of the reissued patent. The Federal Circuit concluded that, where both the original and reissued patents claimed a drug product under regulatory review, using the issue date of the original patent to calculate PTE comports with both the purpose of the Hatch-Waxman Act and the related statutory context.

...

Read More

IP Newsflash

May 12, 2025

The Patent Trial and Appeal Board recently declined to institute a petition for IPR that was filed on the same day that the petitioner filed another petition challenging the same claims of the same patent. The board was not persuaded by petitioner’s arguments that a second petition was needed due to alleged claim construction issues or the number, length or scope differences of the challenged claims.

...

Read More

© 2025 Akin Gump Strauss Hauer & Feld LLP. All rights reserved. Attorney advertising. This document is distributed for informational use only; it does not constitute legal advice and should not be used as such. Prior results do not guarantee a similar outcome. Akin is the practicing name of Akin Gump LLP, a New York limited liability partnership authorized and regulated by the Solicitors Regulation Authority under number 267321. A list of the partners is available for inspection at Eighth Floor, Ten Bishops Square, London E1 6EG. For more information about Akin Gump LLP, Akin Gump Strauss Hauer & Feld LLP and other associated entities under which the Akin Gump network operates worldwide, please see our Legal Notices page.